A message from our partners at Huge Alerts 
BSEM Accelerates into Advanced and Acute Wound Care with BioTissue Acquisition, Seven Consecutive Profitable Quarters, and Institutional-Grade Growth Prospects. BioStem Technologies (OTCQB: BSEM) is rapidly transforming from a niche regenerative medicine company into a full-spectrum MedTech player. Its acquisition of BioTissue Holdings’ surgical and wound care assets brings products like Neox® and Clarix® to the forefront, giving BioStem immediate access to hospital-based and surgical markets. Combined with a nationwide sales network and existing GPO contracts, this deal expands BSEM’s total addressable market to $300–$350 million while creating synergies across chronic, acute, and surgical wound care solutions. Financially disciplined and clinically validated, BioStem has delivered seven profitable quarters in a row, with strong margins, positive EBITDA, and $16 million in cash on hand post-acquisition. Its proprietary BioREtain® technology is supported by FDA-level randomized controlled trials, reinforcing adoption among physicians and payors in a results-driven healthcare landscape. With a Nasdaq uplisting on the horizon and a Zacks $25.50 target, BioStem is establishing itself as a compelling small-cap growth story. Learn why BSEM is a MedTech company that could see accelerated 2026 growth.
Exclusive Story from MarketBeat.com Synopsys: Long-Term Opportunity Outweighs Near-Term HeadwindsBy Leo Miller. Published: 2/27/2026. 
Key Points - NVIDIA-backed Synopsys has struggled as of late, but still maintains a dominant position in a key part of the semiconductor industry.
- The firm's Ansys acquisition is progressing, with new product monetization set for 2027.
- Synopsys' long-term outlook remains positive, with the stock trading at depressed valuation multiples compared to its history.
- Special Report: Elon Musk's New 1,000X Opportunity (From Brownstone Research)
 Electronic design automation (EDA) stock Synopsys (NASDAQ: SNPS) has been in a rut over the last several months. While EDA revenue growth remains strong, the firm's intellectual property revenue is declining — in part due to struggles at one of Synopsys's major semiconductor customers, Intel (NASDAQ: INTC). The company also gained approval for its $35 billion acquisition of Ansys; that transaction has been a near-term profitability headwind. Still, there are plenty of reasons for optimism. Synopsys is one of the dominant players in EDA, a technology that is essential to semiconductor design. The Ansys deal expands the company's total addressable market from chips to full-system development, and NVIDIA (NASDAQ: NVDA) invested $2 billion in the firm, signaling confidence in the combined business. Below we review Synopsys's latest financial results and the implications of the Ansys acquisition to assess the company's outlook. SNPS Posts Beats, But Shares Falter on Modest Guidance Increase In its fiscal Q1 2026 (note that Synopsys's fiscal year differs from the calendar year), the company reported revenue of $2.41 billion, slightly above estimates of $2.39 billion. Overall revenue rose 66%, but much of that increase reflected the addition of Ansys. Adjusted earnings per share (EPS) rose 24% to $3.77, topping the consensus of $3.56 (which implied roughly 17% growth). On an organic basis, EDA sales increased 12% — a solid but not spectacular result. Design IP sales declined 6%, in line with management's characterization of 2026 as a "transition year" for that segment. Notably, this was the segment's best performance in the last five quarters; in three of the prior five quarters, Design IP sales fell by 15% or more. Despite the beats, Synopsys shares fell roughly 5% after the release. Several factors contributed. Although Q1 included an adjusted EPS beat of over $0.20, the company raised the midpoint of its full-year EPS guidance by only $0.06, suggesting management does not expect Q1's benefits to persist throughout the year. In addition, NVIDIA reported on the same day and experienced a sell-off; given NVIDIA's significance to the semiconductor ecosystem, that weakness likely weighed on Synopsys as well. Ansys: Near-Term Profitability Headwind Since the acquisition closed, Synopsys's GAAP operating margin has been pressured. In fiscal Q2 2025, the company's operating margin was 23.5%, but by fiscal Q4 2025 it had fallen to 5.4% as Ansys costs were consolidated before synergies and new products could be realized. Encouragingly, the non-adjusted operating margin improved by 300 basis points in the most recent quarter to 8.4%, which suggests profitability is beginning to recover. The more meaningful benefits from the Ansys transaction are expected to emerge over the medium to long term. Synopsys expects $400 million in cost synergies by year three and $400 million in revenue synergies by year four. Achieving those targets will require streamlining operations (including headcount reductions) and developing combined products; Synopsys plans to launch joint offerings in 2026 and begin monetizing them in fiscal 2027. Ansys: Major Long-Term Addressable Market Tailwind The combination of higher revenue potential and lower costs would significantly aid Synopsys's profitability recovery. Beyond that, the strategic rationale for the deal is compelling. Synopsys's EDA tools focus on designing chips — the "brains" of computing systems. Increasingly, those brains are integrated into complex machines such as autonomous vehicles, drones, and robots that must meet physical constraints like size, power consumption, and thermal dissipation. Synopsys argues it is more efficient to design the "brain" and the "body" of these machines together rather than separately. By combining Ansys's physics simulation software with Synopsys's EDA offerings, engineers can evaluate how physical limitations will affect a system before building it. That reduces the risk of designing a chip and supporting system independently only to discover integration problems later. Fewer mistakes mean lower costs, creating a clear incentive for adopters to choose Synopsys's integrated tools. As systems grow more complex, Synopsys's ability to offer end-to-end system design should expand its addressable market. SNPS: A Long-Term Tech Winner Although Synopsys has underperformed recently, its long-term prospects remain attractive. The stock now trades at a forward price-to-earnings ratio near 28x, below its three-year average of about 36x. This relative undervaluation, combined with a leading market position in EDA and an expanded TAM from the Ansys acquisition, makes the long-term opportunity in Synopsys more compelling for investors willing to look past near-term integration headwinds.
| 
